

# SHANMUGA HOSPITAL LIMITED

(Erstwhile known as Shanmuga Hospital Private Limited)



Our company was originally incorporated as a Private Limited Company under the name "Shanmuga Hospital Private Limited" on June 26, 2020, in accordance with the Companies Act, 2013. We received a fresh certificate of incorporation, bearing the corporate identification number U85110TZ2020PTC033974, from the Registrar of Companies, Central Registration Centre. Subsequently, our company converted into a public limited company, resulting in a name change to "Shanmuga Hospital Limited." This alteration was formally recorded in a new Certificate of Incorporation dated June 06, 2024, with the Corporate Identification Number U85110TZ2020PLC033974, issued by the Registrar of Companies, Central Processing Centre. For further details of change in name and registered office of our company, please refer to section titled "Our History and Certain Corporate Matters" beginning on page no 159 of the Prospectus.

**Registered & Corporate Office:** 51/24, Saradha College Road, Salem - 636007, Tamil Nadu, India **Contact Person:** Mr. Veera Pratap Reddy Gandluru, Company Secretary & Compliance Officer;  
**Tel No:** +91 427 2706674, **E-Mail ID:** cs@smrft.org **Website:** www.shanmugahospital.com; **CIN:** U85110TZ2020PLC033974

**OUR PROMOTERS: (I) DR. PANNEERSELVAM PALANAPPAN SHANMUGAM; (II) DR. PRABU SANKAR PANNEERSELVAM; (III) DR. PRIYADHARSHNI DHANDAPANI; AND (IV) MRS. JAYALAKSHMI PANNEERSELVAM**

**THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE LIMITED (BSE SME).**

## BASIS OF ALLOTMENT

INITIAL PUBLIC OFFER OF UP TO 38,18,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH ("EQUITY SHARES") OF SHANMUGA HOSPITAL LIMITED (THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹54/- PER EQUITY SHARE, INCLUDING A SHARE PREMIUM OF ₹44/- PER EQUITY SHARE (THE "ISSUE PRICE"), AGGREGATING TO ₹ 2,061.72 LAKHS ("THE ISSUE"), OF WHICH 1,92,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH FOR CASH AT A PRICE OF ₹54/- PER EQUITY SHARE, AGGREGATING TO ₹ 103.68 LAKHS IS RESERVED FOR SUBSCRIPTIONS BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 36,26,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH FOR CASH AT A PRICE OF ₹54/- PER EQUITY SHARE, AGGREGATING TO ₹ 1,958.04 LAKHS IS HERE IN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE CONSTITUTES 28.05% AND 26.64% RESPECTIVELY OF THE POST ISSUE PAIDUP EQUITY SHARE CAPITAL OF THE COMPANY.

THE FACE VALUE OF THE EQUITY SHARE IS ₹10/- EACH AND THE ISSUE PRICE IS ₹ 54/- EACH i.e., 5.4 TIMES OF THE FACE VALUE OF THE EQUITY SHARES. THE MINIMUM LOT SIZE IS 2,000 EQUITY SHARES  
 ISSUE PROGRAMME: ISSUE OPENED ON FEBRUARY 13, 2025 AND CLOSED ON FEBRUARY 17, 2025,  
 PROPOSED DATE OF LISTING : FEBRUARY 21, 2025 \*

## RISKS TO INVESTORS

- Our Company, Directors, Promoters and Group Companies are parties to certain legal proceedings. Any adverse decision in such proceedings may have a material adverse effect on our business, results of operations and financial condition.
- Our Company has limited operating history, and therefore investors may not be able to assess our prospects on the basis of historical results.
- We are highly dependent on our healthcare professionals, including doctors, nurses that we engage on a consultancy basis, and our business and financial results could be impacted if we are not able to attract and retain such healthcare professionals.
- Our Company is yet to place orders for medical equipment proposed to be installed at our hospital. Any delay in placing orders or procurement of such equipment may delay the schedule of implementation and possibly increase the cost of commencing operations.
- We generate certain revenues from the arrangements with government sponsored health schemes, any adverse change in these regulations/government policies related to such schemes may adversely affect our business, results of operations, cash flows and prospects.

For further details please refer to the chapter "Risk Factors" on page no. 23 of the Prospectus

The Equity Shares offered through Prospectus are proposed to be listed on the SME Platform of BSE Limited ("BSE SME"). Our Company has received in-principal approval letter dated January 22, 2025 from BSE for using its name in this offer document for listing of our shares on the BSE SME. For the purpose of this Issue, the Designated Stock Exchange is the BSE Limited ("BSE"). The trading is proposed to commence on February 21, 2025.

\* Subject to receipt of listing and trading approvals from the BSE Limited.

## SUBSCRIPTION DETAILS

The Issue was subscribed to an extent of 4.88 times i.e., Gross Subscription of Rs. 1,00,65,60,000/- for 1,86,40,000 equity shares were based on the bid file received from BSE on the day after closure of the Issue received as against Rs. 20,61,72,000/- for 38,18,000 equity shares equity shares. (including subscription by Market Makers to the Issue). The Issue was subscribed to an extent of 2.36 times (after technical rejection and bids not banked). i.e. Net Subscription of Rs. 48,77,28,000/- for 90,32,000 equity shares after eliminating technically rejected and bid not banked applications.

## Summary of the Valid Applications Received:

Sr. No	Category	Gross Application		Less: Rejections		Valid		Allotment	
		No. of Application	Equity Share	No. of Application	Equity Share	No. of Application	Equity Share	No. of Application	Equity Share
1	Retail Individual Applicants	4,041	80,82,000	181	3,62,000	3,860	77,20,000	1,590	31,80,000
2	Non Retail Applicants (Non Institutional Applicants and QIBs)	202	11,02,000	3	16,000	199	10,86,000	172	4,46,000
3	Market Maker	1	1,92,000	0	0	1	1,92,000	1	1,92,000
	<b>Total</b>	<b>4,244</b>	<b>93,76,000</b>	<b>184</b>	<b>3,78,000</b>	<b>4,060</b>	<b>89,98,000</b>	<b>1,763</b>	<b>38,18,000</b>

**Allocation:** The Basis of Allotment was finalized in consultation with the Designated Stock Exchange – BSE on February 18, 2025.

**A. Allocation to Market Maker (After Technical & Multiple Rejections and Withdrawal):** The Basis of Allotment to the Market Maker, at the issue price of ₹ 54/- per Equity Share, was finalized in consultation with BSE. The category was subscribed by 1.00 time. The total number of shares allotted in this category is 1,92,000 Equity shares.

Sr. No	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied	% to total	Allocation per Applicant		Ratio of allottees to applicants	Number of successful applicants (after rounding)	Total No. of shares allocated/ allotted
						Before rounding off	After rounding off			
1	192000	1	100	192000	100	192000	192000	1	1	192000
	<b>GRAND TOTAL</b>	<b>1</b>	<b>100</b>	<b>192000</b>	<b>100</b>				<b>1</b>	<b>192000</b>

**B. Allocation to Retail Individual Investors (After Technical & Multiple Rejections and Withdrawal):** The Basis of Allotment to the Retail Individual Investors, at the issue price of ₹ 54/- per Equity Share, was finalized in consultation with BSE. The category was subscribed by 2.427 times i.e. for 77,20,000 Equity Shares. Total number of shares allotted in this category is 31,80,000 Equity Shares to 1,590 successful applicants.

Sr. No	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Allocation per Applicant		Ratio of allottees to applicants	Number of successful applicants(after rounding)	Total No. of shares allocated/ allotted
						Before rounding off	After rounding off			
1	2000	3860	100	7720000	100	823.8342	2000	159	386	1590
	<b>GRAND TOTAL</b>	<b>3860</b>	<b>100</b>	<b>7720000</b>	<b>100</b>				<b>1590</b>	<b>3180000</b>

**C. Allocation to Non Retail Applicants (Non Institutional Applicants and QIBs) (After Technical Rejections & Withdrawal):** The Basis of Allotment to Other than Retail Individual Investors, at the issue price of ₹ 54/- per Equity Share, was finalized in consultation with BSE. The category was subscribed by 2.434 times i.e. for 10,86,000 Equity Shares. Total number of shares allotted in this category is 4,46,000 Equity Shares to 172 successful applicants.

The category wise details of the Basis of Allotment are as under:

Sr. No	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Allocation per Applicant After rounding off		Ratio of allottees to applicants	Number of successful applicants (after rounding)	Total No. of shares allocated/ allotted
						Before Rounding off	After Rounding off			
1	4000	149	74.87	596000	54.88	1642.73	2000	122	149	122
2	6000	15	7.54	90000	8.29	2464.09	2000	1	1	15
3			7.54	90000	8.29	2464.09	2000	3	15	3
4	8000	17	8.54	136000	12.52	3285.45	2000	1	1	17
5			8.54	136000	12.52	3285.45	2000	11	17	11
6	10000	5	2.51	50000	4.60	4106.81	4000	1	1	5
7	12000	5	2.51	60000	5.52	4928.18	4000	1	1	5
8			2.51	60000	5.52	4928.18	2000	2	5	2
9	14000	1	0.50	14000	1.29	5749.54	6000	1	1	1
10	18000	1	0.50	18000	1.66	7392.27	8000	1	1	1
11	20000	5	2.51	100000	9.21	8213.63	8000	1	1	5
12			2.51	100000	9.21	8213.63	2000	1	5	1
13	22000	1	0.50	22000	2.03	9034.99	10000	1	1	1
Total		199	100.00	1086000	100.00				172	446000

The Board of Directors of the company at its meeting held on February 18, 2025 has approved the Basis of Allotment of Equity shares as approved by the Designated stock Exchange viz. BSE and at a meeting held on February 18, 2025 has authorized the corporate action for the transfer and allotment of the Equity Shares to various successful applicants.

In terms of the Prospectus dated February 06, 2025 and as per the SEBI (ICDR) Regulations wherein a minimum of 50% of the net offer of shares to the Public shall initially be made available for allotment to retail individual investors as the case may be. The balance net offer of shares to the public shall be made available for allotment to a) individual applicants other than retail investors and b) other investors, including Corporate Bodies / Institutions irrespective of number of shares applied for. The unsubscribed portion of the net offer to any one of the categories specified in (a) or (b) shall be made available for allocation in the other category, if so required. "For the purpose of sub-regulation (2) of regulations 253, if the retail individual investor category is entitled to more than fifty per cent on proportionate basis, the retail individual investors shall be allocated that higher percentage".

The instructions to Self Certified Syndicate Banks for unblocking the amount has been processed on February 18, 2025. Further, the CAN-cum-Refund advices and allotment advice and/or notices has been forwarded to the address/ email id of the Applicants as registered with the depositories as filled in the application form on February 18, 2025. In case the same is not received within 10 days, investors may contact at the address given below. The Equity Shares allocated to successful applicants are being credited to their beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is taking steps to get the Equity Shares admitted for trading on the BSE within three working days from the date of the closure of the Issue.

**Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus dated February 06, 2025 ("Prospectus")**

**The Lead Manager associated with the Offer have handled 29 SME public issues and Nil Main Board public issue during the current financial year and three financial years preceding the current Financial Year, out of which 7 SME public issues closed below the issue price on the listing date.**

Type	FY 2024-25*	FY 2023-24	FY 2022-23	FY 2021-22	Total
SME IPO	5	5	12	7	29
Main Board IPO	-	-	-	-	-
<b>Total</b>	<b>5</b>	<b>5</b>	<b>12</b>	<b>7</b>	<b>29</b>
Issue closed Below Issue Price on Listing Day	-	-	5	2	7
Issue closed above Issue Price on Listing Day	5	5	7	5	22

\* Status as on February 05, 2025

**INVESTORS PLEASE NOTE** The details of the allotment made would also be hosted on the website of the Registrar to the Issuer, [www.integratedregistry.in](http://www.integratedregistry.in) All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/ Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:



## INTEGRATED REGISTRY MANAGEMENT SERVICES PRIVATE LIMITED

No 30, Ramana Residency, 4th Cross, Sampige Road, Malleswaram, Bengaluru – 560003, India

**Telephone:** 080-23460815/816/817/818 **Email:** smeipo@integratedindia.in **Contact Person:** S Giridhar **Website:** www.integratedregistry.in

**Investor Grievance Email:** giri@integratedindia.in **SEBI Registration Number:** INR000000544 **CIN:** U74900TN2015PTC101466

For SHANMUGA HOSPITAL LIMITED

On behalf of the Board of Directors

Sd/-

Dr. Prabu Sankar Panneerselvam

Executive Director & CEO

DIN: 08772888

Place : Salem, Tamil Nadu

Date : February 19, 2025

**DISCLAIMER CLAUSE OF BSE:** IT IS TO BE DISTINCTLY UNDERSTOOD THAT THE PERMISSION GIVEN BY BSE LIMITED ("BSE") SHOULD NOT IN ANY WAY BE DEEMED OR CONSTRUED THAT THE CONTENTS OF THE PROSPECTUS OR THE PRICE AT WHICH THE EQUITY SHARES ARE OFFERED HAS BEEN CLEARED, SOLICITED OR APPROVED BY BSE, NOR DOES IT CERTIFY THE CORRECTNESS, ACCURACY OR COMPLETENESS OF ANY OF THE CONTENTS OF THE PROSPECTUS. THE INVESTORS ARE ADVISED TO REFER TO THE PROSPECTUS FOR THE FULL TEXT OF THE DISCLAIMER CLAUSE PERTAINING TO BSE.

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF SHANMUGA HOSPITAL LIMITED